drugset / Trial / NCT07834398
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.
Timeline
- Start
- 2025-11-14
- Primary completion
- 2026-04-13
- Completion
- 2026-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |
| Comparator | Tirzepatide | Peptide | 15 mg | Subcutaneous |